Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1324
Name lung cancer
Definition A respiratory system cancer that is located_in the lung.
Source DiseaseOntology.org
Alt Ids DOID:13075 DOID:9881 DOID:1322
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047R Dactolisib lung cancer sensitive detail...
PIK3CA H1047R Sirolimus lung cancer no benefit detail...
EML4 - ALK ALK G1202R Lorlatinib lung cancer conflicting detail...
FGFR1 amp Brivanib lung cancer no benefit detail...
ATR positive Berzosertib + Cisplatin lung cancer sensitive detail...
STK11 loss unspecified PD-1 antibody lung cancer resistant detail...
FGFR1 amp AZD4547 lung cancer sensitive detail...
FGFR1 wild-type AZD4547 lung cancer decreased response detail...
TP53 wild-type KRT-232 lung cancer sensitive detail...
TP53 loss KRT-232 lung cancer resistant detail...
TP53 wild-type KRT-232 + Radiotherapy lung cancer sensitive detail...
TP53 loss KRT-232 + Radiotherapy lung cancer resistant detail...
CDKN2A del PF-00477736 + PF3644022 lung cancer predicted - sensitive detail...
EML4 - ALK X-376 lung cancer sensitive detail...
FGFR1 amp Erdafitinib lung cancer predicted - sensitive detail...
FGFR1 amp GSK3052230 lung cancer sensitive detail...
BRAF V600E KEAP1 loss Trametinib lung cancer decreased response detail...
BRAF V600E KEAP1 loss Vemurafenib lung cancer decreased response detail...
KEAP1 loss NRAS Q61K Trametinib lung cancer decreased response detail...
EML4 - ALK KEAP1 dec exp Crizotinib lung cancer sensitive detail...
EML4 - ALK KEAP1 dec exp Ceritinib lung cancer decreased response detail...
BRAF V600E Ulixertinib lung cancer sensitive detail...
BRAF L597Q Ulixertinib lung cancer sensitive detail...
CTNNB1 T41A NTRC 0066-0 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps-BAY2b lung cancer predicted - sensitive detail...
CTNNB1 T41A NMS-P715 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1161909 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1217389 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps1-IN-1 lung cancer predicted - sensitive detail...
CTNNB1 T41A MPI-0479605 lung cancer predicted - sensitive detail...
NRAS Q61K RAF709 lung cancer sensitive detail...
ATM positive AZD1390 lung cancer sensitive detail...
FGFR1 amp PD173074 lung cancer sensitive detail...
BRAF G469A RMC-4550 lung cancer resistant detail...
BRAF G466V RMC-4550 lung cancer predicted - sensitive detail...
CD274 positive MCLA-145 lung cancer predicted - sensitive detail...
EML4 - ALK ALK L1152R Ceritinib lung cancer resistant detail...
MAP2K1 E41_L54del Trametinib lung cancer sensitive detail...
MAP2K1 E41_L54del Cobimetinib lung cancer sensitive detail...
MAP2K1 E41_L54del Selumetinib lung cancer sensitive detail...
MAP2K1 E41_L54del LY3009120 lung cancer no benefit detail...
FGFR1 amp FGFR1 over exp Rogaratinib lung cancer sensitive detail...
FGFR1 amp FGFR1 over exp Docetaxel + Rogaratinib lung cancer sensitive detail...
FGFR1 amp FGFR1 over exp Carboplatin + Paclitaxel + Rogaratinib lung cancer sensitive detail...
FGFR1 over exp Rogaratinib lung cancer predicted - sensitive detail...
FGFR1 over exp Docetaxel + Rogaratinib lung cancer predicted - sensitive detail...
BRAF G466V PLX8394 lung cancer predicted - sensitive detail...
EML4 - ALK Bevacizumab + Lorlatinib lung cancer predicted - sensitive detail...
MAP2K1 Q56P LY3214996 lung cancer predicted - sensitive detail...
FGFR1 amp Futibatinib lung cancer predicted - sensitive detail...
EML4 - ALK Alectinib lung cancer predicted - sensitive detail...
BRAF G466V CFT1946 lung cancer predicted - sensitive detail...
FGFR1 amp 3D185 lung cancer sensitive detail...
TP53 del M8891 lung cancer resistant detail...
PBRM1 loss PRT1419 + Sunitinib lung cancer sensitive detail...
PBRM1 loss PRT2527 lung cancer sensitive detail...
PBRM1 loss PRT2527 + Sunitinib lung cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed USA | FRA | BEL 1
NCT01470209 Phase I Buparlisib + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed USA 0
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Completed USA 0
NCT01935336 Phase II Ponatinib Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Completed USA 0
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated USA 0
NCT02155465 Phase Ib/II Erlotinib + Ruxolitinib Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Completed USA 0
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed USA 0
NCT02264236 Phase Ib/II Montanide ISA 51 + P10s-PADRE Vaccination of Advanced-Stage Lung Cancer Patients Withdrawn USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02429843 Phase I Carboplatin + Paclitaxel Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Completed USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Recruiting USA 0
NCT02768337 Phase Ib/II Afatinib Cambridge Brain Mets Trial 1 (CamBMT1) Terminated GBR 0
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03373760 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Completed USA 0
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Terminated USA 0
NCT03597009 Phase Ib/II Nivolumab + Talimogene laherparepvec A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Terminated USA 0
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Active, not recruiting USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT04085315 Phase I Alisertib + Osimertinib Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Active, not recruiting USA 0
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Completed USA | GBR | AUS 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Active, not recruiting USA | GBR | ESP | DEU 1
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04287868 Phase Ib/II Bintrafusp alfa + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Active, not recruiting USA 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Completed USA | CAN 0
NCT04713891 Phase I KF-0210 Atezolizumab + KF-0210 A Study of KF-0210 in Advanced Solid Tumors Patients Unknown status AUS 0
NCT05060432 Phase Ib/II EOS-448 + Pembrolizumab EOS-448 + EOS100850 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) Recruiting USA | ITA | GBR | FRA | ESP | BEL 0
NCT05620342 Phase I iC9.GD2.CAR.IL-15 T-cells Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer Recruiting USA 0
NCT05830097 Phase Ib/II CBP-1019 A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05831995 Phase I ABM-168 Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. Recruiting USA 0
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05892068 Phase II Tucatinib A Study of Tucatinib Given Before Surgery to People With HER2 positive Cancers That Have Spread to the Brain Recruiting USA 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06228326 Phase I KB707 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Recruiting USA 0